GenesisCare announced today that it enrolled the first patients in a trial for Boston Scientific’s (NYSE:BSX) SpaceOAR Vue hydrogel.
Boston Scientific’s SpaceOAR Vue hydrogel will be evaluated in the SABRE trial, sponsored by Boston Scientific, for prostate cancer patients receiving stereotactic body radiation therapy (SBRT).
